Efficacy and safefy of Polymyxin B treatment for neutropenic patients suffering from refractory Gram-negative bacterial bloodstream infection.

Meng Zhou; Hui Zhu Kang; Cheng Yuan GU; Yue Jun Liu; Ying Wang; Miao Miao; Jian Hong FU; Xiao Wen Tang; Hui Ying Qiu; Cheng Cheng FU; Zheng Ming Jin; Cai Xia LI; Su Ning Chen; Ai Ning Sun; De Pei WU; Yue Han

Return

Efficacy and safefy of Polymyxin B treatment for neutropenic patients suffering from refractory Gram-negative bacterial bloodstream infection.

Author: Meng ZHOU ¹ ; Hui Zhu KANG ¹ ; Cheng Yuan GU ¹ ; Yue Jun LIU ¹ ; Ying WANG ¹ ; Miao MIAO ¹ ; Jian Hong FU ¹ ; Xiao Wen TANG ¹ ; Hui Ying QIU ¹ ; Cheng Cheng FU ¹ ; Zheng Ming JIN ¹ ; Cai Xia LI ¹ ; Su Ning CHEN ¹ ; Ai Ning SUN ¹ ; De Pei WU ¹ ; Yue HAN ¹
Author Information

1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
Publication Type:Journal Article
Keywords: Bloodstream infection; Neutropenia; Polymyxin B; Refractory Gram-negative bacterium
MeSH: Humans; Polymyxin B/adverse effects*; Retrospective Studies; Gram-Negative Bacterial Infections/complications*; Fever/drug therapy*; Sepsis/drug therapy*; Anti-Bacterial Agents/therapeutic use*; Bacteremia/complications*
From: Chinese Journal of Hematology 2023;44(6):484-489
CountryChina
Language:Chinese
Abstract: Objective: To assess the efficacy and safety of polymyxin B in neutropenic patients with hematologic disorders who had refractory gram-negative bacterial bloodstream infection. Methods: From August 2021 to July 2022, we retrospectively analyzed neutropenic patients with refractory gram-negative bacterial bloodstream infection who were treated with polymyxin B in the Department of Hematology of the First Affiliated Hospital of the Soochow University between August 2021 to July 2022. The cumulative response rate was then computed. Results: The study included 27 neutropenic patients with refractory gram-negative bacterial bloodstream infections. Polymyxin B therapy was effective in 22 of 27 patients. The median time between the onset of fever and the delivery of polymyxin B was 3 days [interquartile range (IQR) : 2-5]. The median duration of polymyxin B treatment was 7 days (IQR: 5-11). Polymyxin B therapy had a median antipyretic time of 37 h (IQR: 32-70). The incidence of acute renal dysfunction was 14.8% (four out of 27 cases), all classified as "injury" according to RIFLE criteria. The incidence of hyperpigmentation was 59.3%. Conclusion: Polymyxin B is a viable treatment option for granulocytopenia patients with refractory gram-negative bacterial bloodstream infections.